Details for Patent: 12,419,895
Which drugs does patent 12,419,895 protect, and when does it expire?
Patent 12,419,895 protects VYKAT XR and is included in one NDA.
This patent has sixty-two patent family members in twenty-one countries.
Summary for Patent: 12,419,895
| Title: | Methods for treating subjects with Prader-Willi syndrome |
| Abstract: | Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like. |
| Inventor(s): | Neil M. Cowen |
| Assignee: | Essentialis Inc |
| Application Number: | US19/224,580 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 12,419,895 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Delivery; |
Drugs Protected by US Patent 12,419,895
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Soleno | VYKAT XR | diazoxide choline | TABLET, EXTENDED RELEASE;ORAL | 216665-001 | Mar 26, 2025 | RX | Yes | No | 12,419,895 | ⤷ Start Trial | TREATING HYPERPHAGIA AND REDUCING FOOD-RELATED BEHAVIORS IN PRADER-WILLI SYNDROME PATIENTS | ⤷ Start Trial | ||||
| Soleno | VYKAT XR | diazoxide choline | TABLET, EXTENDED RELEASE;ORAL | 216665-002 | Mar 26, 2025 | RX | Yes | No | 12,419,895 | ⤷ Start Trial | TREATING HYPERPHAGIA AND REDUCING FOOD-RELATED BEHAVIORS IN PRADER-WILLI SYNDROME PATIENTS | ⤷ Start Trial | ||||
| Soleno | VYKAT XR | diazoxide choline | TABLET, EXTENDED RELEASE;ORAL | 216665-003 | Mar 26, 2025 | RX | Yes | Yes | 12,419,895 | ⤷ Start Trial | TREATING HYPERPHAGIA AND REDUCING FOOD-RELATED BEHAVIORS IN PRADER-WILLI SYNDROME PATIENTS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,419,895
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E463249 | ⤷ Start Trial | |||
| Australia | 2005280058 | ⤷ Start Trial | |||
| Australia | 2010246520 | ⤷ Start Trial | |||
| Australia | 2015346196 | ⤷ Start Trial | |||
| Australia | 2019202906 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
